luspatercept
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
β-Thalassemia
Conditions
β-Thalassemia
Trial Timeline
Oct 20, 2014 → Jun 18, 2020
NCT ID
NCT02268409About luspatercept
luspatercept is a phase 2 stage product being developed by Merck for β-Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02268409. Target conditions include β-Thalassemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03342404 | Phase 2 | Completed |
| NCT02604433 | Phase 3 | Completed |
| NCT02631070 | Phase 3 | Completed |
| NCT02268409 | Phase 2 | Completed |
| NCT02268383 | Phase 2 | Completed |
| NCT01749540 | Phase 2 | Completed |
| NCT01749514 | Phase 2 | Completed |
Competing Products
8 competing products in β-Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 1 | 33 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Luspatercept | Bristol Myers Squibb | Pre-clinical | 22 |
| Luspatercept | Bristol Myers Squibb | Pre-clinical | 22 |
| PTG-300 | Protagonist Therapeutics | Phase 2 | 49 |
| PTG-300 | Protagonist Therapeutics | Phase 2 | 49 |